SpaceX/xAI Merger Creates First "Teracorn" at $1.25T; Anthropic and OpenAI Dominate Private Capital Formation

The Rise of the Teracorn: SpaceX/xAI Merger Reshapes Private Markets February 2026 marked a watershed moment in private market history: SpaceX merged with Elon Musk's AI venture xAI to create the world's first "Teracorn" — a private company valued at over one trillion dollars. The combined entity stands at a staggering $1.25 trillion valuation , surpassing all prior records for a private company. SpaceX has since reportedly filed confidentially for an IPO targeting a June 2026 listing that could raise up to $50 billion — potentially the largest IPO in history, eclipsing Saudi Aramco's $29 billion debut in 2019. Anthropic and OpenAI Set Records of Their Own The AI capital formation frenzy did not stop at SpaceX/xAI. In rapid succession: Anthropic closed a $30 billion raise at a $380 billion valuation, led by Singapore's GIC and Coatue Management. OpenAI announced a $110 billion financing round — the largest private capital raise ever recorded. Together, Anthropic and OpenAI have already raised $140 billion year-to-date in 2026, setting 2026 on pace to shatter all prior records for mid- and late-stage private funding. Capital Concentration at the Top According to Forge Global's March 2026 private market update, SpaceX, OpenAI, and Anthropic now account for 68% of the total valuation of the top 50 private companies . For context, the top three public companies (Nvidia, Apple, and Alphabet) together total $11.96 trillion — suggesting the private market giants still have room to grow post-IPO. Why This Matters for Private Markets The concentration of capital in a handful of AI-driven unicorns is fundamentally altering secondary market dynamics. Pre-IPO secondary trading of SpaceX, OpenAI, and Anthropic shares has become one of the most active segments of the private secondary market, with valuations changing rapidly. Investors seeking liquidity or exposure ahead of the anticipated IPO wave must navigate significant pricing uncertainty and limited supply — but also outsized potential upside.